Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
Senior Staff Scientist
Evaluating the efficacy of MSI-1436 in slowing the progression and in reversing diabetic nephropathy in the BTBR ob/ob mouse
Abstract Diabetic nephropathy (DN) is a major cause of morbidity and mortality in type 1 diabetics and is becoming an increasingly serious problem in type 2 diabetics. DN is characterized by progressive loss of glomerular function due to fibrosis, capillary damage and loss of podocytes and is the primary cause of chronic and end-stage renal disease in the world. Therapies aimed at inducing the regeneration of lost tissues and cells have been proposed as therapeutic strategies for slowing and reversing diabetic glomerular damage. MSI-1436 is a readily synthesized aminosterol isolated from dogfish sharks. We have demonstrated that MSI-1436 induces a 2-3-fold stimulation in regeneration of amputated zebrafish cardiac, nerve, bone, skin, connective and vascular tissues without malformation. In adult mice, MSI-1436 stimulates injured skeletal muscle stem cell activation over 2-fold, and increases survival, improves heart function ~2-fold, stimulates regenerative cardiomyocyte proliferation ~4-fold and reduces infarct size by ~55% 4 weeks after cardiac ischemic injury induced by permanent cardiac artery ligation. MSI-1436 has been studied extensively. The molecule inhibits the tyrosine phosphatase PTP1B and was tested by Genaera Corp. in 2007 in Phase 1 and 1b clinical trials for treatment of obesity and type 2 diabetes. Metabolic changes consistent with inhibition of PTP1B were reported and patients showed no adverse reactions to the drug. Importantly, the stimulatory effects on tissue repair and regeneration we observe in zebrafish and mice occur at doses 5- and 50-times lower than the maximum dose shown previously to be safe in humans. Given the effect of MSI-1436 on animals as diverse as zebrafish and mice and its ability to stimulate repair and regeneration of highly diverse tissues, we postulate that the molecule will stimulate the regeneration of diverse cell types in the diabetic kidney. The overall Aim of this pilot project application is to carry out a proof-of-concept study to test the efficacy of MSI-1436 in slowing and reversing glomerular damage in the BTBR ob/ob mouse. Demonstrated efficacy will provide an essential foundation for more in-depth preclinical studies in order to establish whether MSI-1436 is a candidate for clinical evaluation. The demonstrated safety of MSI-1436 and extensive knowledge of its target and mode of action greatly reduce the time and costs associated with developing this molecule as a regenerative medicine therapy.
Drag a column header and drop it here to group by that column
Evaluating the efficacy of MSI-1436 in slowing the progression and in reversing diabetic nephropathy in the BTBR ob/ob mouse (Yin, Viravuth)
View Progress Report Document
No uploaded documents found.
No publications found.
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Cardiovascular Committee has the principal function of furthering the mission of the consortium with regard to diabetic cardiomyopathy and macrovascular disease.
Curation Flag Information
New comment to be added:
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!